Brendan Smith

Insider Reports History

Location
Lexington, MA
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Brendan Smith:

Company Role Class Num Shares Value Price $ Report Date Ownership
CRISPR Therapeutics AG Chief Financial Officer Common Shares 5,072 $317,015 $62.50 21 Feb 2023 Direct
CRISPR Therapeutics AG Chief Financial Officer Stock Option (Right to Buy) 14,000 07 Oct 2022 Direct
CRISPR Therapeutics AG Chief Financial Officer Restricted Stock Units 11,475 18 Feb 2023 Direct
Translate Bio, Inc. Chief Financial Officer Stcok Option (right to buy) 0 14 Sep 2021 Direct

Insider Reports Filed by Brendan Smith

Symbol Company Period Transactions Value $ Form Type Role Filing Time
CRSP CRISPR Therapeutics AG 18 Feb 2023 3 -$67,178 4 Chief Financial Officer 22 Feb 2023, 16:41
CRSP CRISPR Therapeutics AG 14 Oct 2022 3 -$61,949 4 Chief Financial Officer 18 Oct 2022, 17:38
CRSP CRISPR Therapeutics AG 07 Oct 2022 1 $0 4 Chief Financial Officer 12 Oct 2022, 17:42
CRSP CRISPR Therapeutics AG 16 Aug 2022 1 $0 4 Chief Financial Officer 18 Aug 2022, 17:39
CRSP CRISPR Therapeutics AG 18 Feb 2022 2 $0 4 Chief Financial Officer 22 Feb 2022, 16:44
CRSP CRISPR Therapeutics AG 14 Oct 2021 2 $0 4 Chief Financial Officer 18 Oct 2021, 20:00
CRSP CRISPR Therapeutics AG 14 Oct 2021 0 $0 3 Chief Financial Officer 15 Oct 2021, 20:00
/report/000120919121056064-smith-brendan-2021-09-14 Translate Bio, Inc. 14 Sep 2021 1 $0 4 Chief Financial Officer 14 Sep 2021, 19:33